Pharmaceuticals: Commission refines intellectual property rules

Pharmaceuticals 2018 European Commission

The EPO – European Patent Office, has announced the 15 inventors short-listed for this prestigious prize – pioneers in a range of technical fields, from green plastics and oil-spill clean-up, to pharmaceuticals, medical imaging and satellite navigation. Gert-Jan Gruter (The Netherlands), nominated for the European Inventor Award 2017 in the category “Small and medium-sized enterprises – SMEs”. © European Patent Organisation , 2017 / Source: EC – Audiovisual Service / Photo: Heinz Troll

This article is brought to you in association with the European Commission.

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Supplementary Protection Certificates (SPCs) extend patent protection for medicinal products which must undergo lengthy testing and clinical trials prior to obtaining regulatory marketing approval. Thanks to the waiver, in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed. The waiver will support Europe’s pioneering role in pharmaceutical research and development.

Vice-President Jyrki Katainen, responsible for Jobs, Growth Investment and Competitiveness, said: “Europe is and should remain at the forefront of pharmaceutical research and manufacturing. Our rules on intellectual property protection of pharmaceuticals promote innovation and creativity. We are committed to the core rights and the length of this protection, which remain unchanged. Today we are proposing a well-calibrated adjustment to the current regime to remove a legal barrier that was preventing our companies from competing on equal terms on global markets where competition is fierce. We want to make sure that our pharmaceutical industry reaps the benefits of such competition.”

Elżbieta Bieńkowska, Commissioner for Internal Market, Industry, Entrepreneurship and SMEs, added: “Today’s proposal strikes a balance between the imperative to ensure the attractiveness of Europe for innovative pharmaceutical companies and the urgency to allow EU based generics and biosimilar to compete on the global markets. This will help create growth and high-skilled jobs in the EU. It could generate €1 billion net additional sales per year and up to 25 000 new jobs over 10 years. It will particularly benefit the many small and medium-sized enterprises in the field. In the medium term, more competition will improve patients’ access to a wider choice of medicines and alleviate public budgets.”

With the waiver, intellectual property (IP) protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.

The proposal is accompanied by a series of safeguards which will create transparency and prevent IP-infringing products from entering Member State markets. It goes hand in hand with other EU initiatives to defend Europe’s know-how and innovation leadership and protect patients against counterfeited medicines. It also complements the EU’s overall approach to ensure free and fair trade, characterised by open markets, for EU-based manufacturers.

Today’s proposal amends Regulation 469/2009 on the supplementary protection certificate for medicinal products. Once adopted by the European Parliament and Council, it will be directly applicable in all EU Member States.

Background

EU and global pharmaceutical markets are undergoing profound changes. Global demand for medicines has increased massively, reaching over €1 trillion in 2017. Alongside this, there is a shift towards an ever-greater market share for generics and biosimilars. Traditionally the EU has played a pioneering role in pharmaceutical research and development, including generic medicines and biosimilars. But this leadership position is under threat.

Supplementary protection certificates (SPCs) are an intellectual property right first introduced in the EU in 1992 as an extension to a patent right. Pharmaceutical SPCs aim to offset the loss of effective patent protection for medicines that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.

EU SPC rules are the strongest in the world. While they aim to reward investment in innovation and protect intellectual property, SPCs can put EU based manufacturers of generics and biosimilar at a disadvantage with non-EU based industry, thereby preventing further innovation and job creation in Europe. Indeed, during the SPC period of protection of the product in the EU, EU-based manufacturers of generic and/or biosimilar-related products cannot currently manufacture for any purpose, including export outside the EUto countries where SPC protection has expired or does not exist, while manufacturers based in those non-EU countries can do so. This major competitive disadvantage entails a risk of delocalisation of manufacturing and loss of investment in Europe. The certificate also makes it more difficult for EU manufacturers to enter the EU market immediately after its expiry, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed.

Many SPC protections will start to lapse from 2020, as a significant number of medicinal products will enter the public domain, since their patent or SPC terms will expire. This development will generate significant new market opportunities for generics, and for biosimilars in particular. There is an urgent need to adjust the existing regulation to this situation, as the markets for generics and biosimilars are highly competitive and steadily growing and the investment decisions on the localisation of the production are being made well in advance.

Today’s proposal was announced in the Commission’s 2015 Single Market Strategy, and follows various studies, an extensive consultation and a European Parliament resolution endorsing the need to introduce before 2019 an SPC manufacturing waiver.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Featured Stings

Diana in Vietnam

Did young people just kill television?

Why exchange programs are essential for the medical students of the 21st century

Qualcomm to be the next target of EU antitrust regulators? China might be the answer

The gender gap of medicine in 2018

Movius @ MWC14: Discussing novel Communications Applications over a “CAFÉ”

Why impoverishment and social exclusion grow in the EU; the affluent north also suffers

The West cannot ignore Russia; dazed Germany sitting on the fence

The energy industry is changing. Are governments switched on?

Draghi cuts the Gordian knot of the Banking Union

Building cybersecurity capacity through benchmarking: the Global Cybersecurity Index

Brexit: The Conservative Party drives the UK and Europe to a perilous road

To end deforestation, we must protect community land rights

Consumers suffer three defeats

EU and Amazon cut deal to end antitrust investigation over e-books deals

American negotiators can’t pay for their trip to Brussels, EU-US trade agreement freezes

Professional practices of primary health care for Brazilian health and gender inequality

EU security and defence industry prepares positions for ‘producers’ and ‘customers’

EU Commission retracts on the Chinese solar panel case

UN humanitarian coordinator condemns Central African Republic hospital attack as ‘inhuman and unworthy’

The Ukrainian crisis to destabilize Europe and the world for a long time

AIESEC @ European Business Summit 2014: European Youth, Change Now Patiently

Eurozone: Retail sales betray economic frailty

Theresa May in search of a magic plan to invoke Article 50 and start Brexit negotiations now

My Mothers

EU continues targeting on Chinese steel imports instead of the revival of its own economy

Is Eurozone heading for disinflation?

Around 2.5 billion more people will be living in cities by 2050, projects new UN report

Counting unemployment in the EU: The real rate comes to anything between 16.1% and 20.6%

Is there a way out of the next financial crisis? Can more printed money or austerity save us all?

The key takeaways of G7 Summit in Canada

Does the West play the Syrian game in Egypt?

“Will TTIP solve the massive EU-US unemployment? Absolutely not!” A revealing Sting Exclusive with Tim Bennett from the Transatlantic Business Council

Is a full course lunch, a new Commissioner and 2 million anti-TTIP citizens what you would call a “Fresh Start”?

€5 billion of EU energy efficiency project money spent on “comfort”

Eurozone economy desperately needs internally driven growth

Commission facilitates the activities of ‘merchants of labour’

The banks first to benefit from the new euro trillion ECB plans to print

What fighting malaria can teach us about linking purpose and business

Google and Apple suddenly realise that doing business in EU is tough?

Vendor Pulse – 2000

The European Parliament fails to really restrict the rating agencies

A Sting Exclusive: EU Commission’s Vice President Šefčovič accentuates the importance of innovation to EU’s Energy Union

New skills needed for medical students in Industry 4.0

Trump’s pounding of Iran less harsh than expected, leaves arrangement open

FIAT Chrysler: from Geneva Motor show to the World, and back

Central Africa Republic: Violence drives thousands of refugees into neighbouring DR Congo, says UN agency

Will Cameron succeed in keeping UK inside the EU and reverse the present economic downturn?

Greece: The new government of Alexis Tsipras shows its colors

Politics still matter in the US but not in Europe

Yellen and Draghi tell Trump and markets not to expedite the next crisis

GSMA announces new keynote speakers for 2018 Mobile World Congress

Ecofin: ‘The Friday battle’ for the banking union

Commission caps charges on card and Internet payments and enforces competition

China and UK relations post Brexit as EU addresses Chinese takeovers

Eurostat overturns Commission’s assessment of the economy

China’s New Normal and Its Relevance to the EU

Trump systematically upsets global order and trade: Where does this end?

Eurozone and Britain heading in different directions

Is the ECB enforcing the will of the big Eurozone member states on the small? Can the euro area live with that?

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s